JP2022501368A5 - - Google Patents
Info
- Publication number
- JP2022501368A5 JP2022501368A5 JP2021515473A JP2021515473A JP2022501368A5 JP 2022501368 A5 JP2022501368 A5 JP 2022501368A5 JP 2021515473 A JP2021515473 A JP 2021515473A JP 2021515473 A JP2021515473 A JP 2021515473A JP 2022501368 A5 JP2022501368 A5 JP 2022501368A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- administration
- patient
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024062468A JP2024096134A (ja) | 2018-09-20 | 2024-04-09 | チカグレロル活性を逆転させる方法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862733892P | 2018-09-20 | 2018-09-20 | |
| US62/733,892 | 2018-09-20 | ||
| US201962806225P | 2019-02-15 | 2019-02-15 | |
| US62/806,225 | 2019-02-15 | ||
| US201962836373P | 2019-04-19 | 2019-04-19 | |
| US62/836,373 | 2019-04-19 | ||
| PCT/US2019/052173 WO2020061465A1 (en) | 2018-09-20 | 2019-09-20 | Methods of reversing ticagrelor activity |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024062468A Division JP2024096134A (ja) | 2018-09-20 | 2024-04-09 | チカグレロル活性を逆転させる方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022501368A JP2022501368A (ja) | 2022-01-06 |
| JP2022501368A5 true JP2022501368A5 (https=) | 2022-09-27 |
| JP7478975B2 JP7478975B2 (ja) | 2024-05-08 |
Family
ID=69887913
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021515473A Active JP7478975B2 (ja) | 2018-09-20 | 2019-09-20 | チカグレロル活性を逆転させる方法 |
| JP2024062468A Pending JP2024096134A (ja) | 2018-09-20 | 2024-04-09 | チカグレロル活性を逆転させる方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024062468A Pending JP2024096134A (ja) | 2018-09-20 | 2024-04-09 | チカグレロル活性を逆転させる方法 |
Country Status (12)
| Country | Link |
|---|---|
| EP (2) | EP4653465A3 (https=) |
| JP (2) | JP7478975B2 (https=) |
| KR (2) | KR102880762B1 (https=) |
| CN (1) | CN113194821B (https=) |
| AU (1) | AU2019342755B2 (https=) |
| CA (1) | CA3113654A1 (https=) |
| DK (1) | DK3852617T3 (https=) |
| ES (1) | ES3042247T3 (https=) |
| FI (1) | FI3852617T3 (https=) |
| MX (1) | MX2021003298A (https=) |
| PL (1) | PL3852617T3 (https=) |
| WO (1) | WO2020061465A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6799530B2 (ja) | 2014-10-01 | 2020-12-16 | メディミューン リミテッド | チカグレロルに対する抗体および使用方法 |
| KR102880762B1 (ko) * | 2018-09-20 | 2025-11-03 | 에스에프제이 파마 엑스, 인코포레이티드 | 티카그렐러 활성을 반전시키는 방법 |
| EP4337253A4 (en) * | 2021-05-10 | 2025-03-19 | Sfj Pharmaceuticals X, Ltd. | Pharmacokinetic & pharmacodynamic model for determining effective dose of anti-ticagrelor antibody |
| KR102952285B1 (ko) | 2021-07-13 | 2026-04-13 | 주식회사 엘지에너지솔루션 | 전지의 용접 상태 검사 방법 |
| WO2026019858A1 (en) * | 2024-07-16 | 2026-01-22 | SFJ Pharma X, Inc. | Methods of reversing ticagrelor activity |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH03154867A (ja) * | 1989-11-13 | 1991-07-02 | Teijin Ltd | １―メチルアデノシンの免疫学的測定方法，そのための測定試薬及び試薬キット |
| US9101642B2 (en) | 2011-06-01 | 2015-08-11 | Astrazeneca Ab | Ticagrelor co-crystal |
| JP2016502526A (ja) * | 2012-11-16 | 2016-01-28 | ノバルティス アーゲー | 末梢動脈疾患を処置するためのＩＬ−１β結合抗体の使用 |
| WO2016033424A1 (en) * | 2014-08-29 | 2016-03-03 | Genzyme Corporation | Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b |
| JP6799530B2 (ja) * | 2014-10-01 | 2020-12-16 | メディミューン リミテッド | チカグレロルに対する抗体および使用方法 |
| AU2016210973B2 (en) * | 2015-01-27 | 2019-02-14 | Astrazeneca Ab | Method of treating or prevention of atherothrombotic events in patients with history of myocardial infarction |
| KR101916956B1 (ko) * | 2016-12-13 | 2018-11-08 | 보령제약 주식회사 | 티카그렐러의 신규한 고체 형태 및 이의 제조방법 |
| IL267519B2 (en) * | 2016-12-23 | 2025-04-01 | Novartis Ag | Factor XI/XIA for use in the prevention, treatment, management, or reduction of the risk of stroke or thromboembolism in a patient with end-stage renal disease |
| BR112019018022A2 (pt) | 2017-03-01 | 2020-06-02 | Medimmune Limited | Formulações de anticorpos monoclonais |
| KR102880762B1 (ko) * | 2018-09-20 | 2025-11-03 | 에스에프제이 파마 엑스, 인코포레이티드 | 티카그렐러 활성을 반전시키는 방법 |
-
2019
- 2019-09-20 KR KR1020217011614A patent/KR102880762B1/ko active Active
- 2019-09-20 ES ES19863329T patent/ES3042247T3/es active Active
- 2019-09-20 PL PL19863329.9T patent/PL3852617T3/pl unknown
- 2019-09-20 DK DK19863329.9T patent/DK3852617T3/da active
- 2019-09-20 CA CA3113654A patent/CA3113654A1/en active Pending
- 2019-09-20 KR KR1020257035868A patent/KR20250161038A/ko active Pending
- 2019-09-20 MX MX2021003298A patent/MX2021003298A/es unknown
- 2019-09-20 CN CN201980075991.0A patent/CN113194821B/zh active Active
- 2019-09-20 FI FIEP19863329.9T patent/FI3852617T3/fi active
- 2019-09-20 WO PCT/US2019/052173 patent/WO2020061465A1/en not_active Ceased
- 2019-09-20 JP JP2021515473A patent/JP7478975B2/ja active Active
- 2019-09-20 AU AU2019342755A patent/AU2019342755B2/en active Active
- 2019-09-20 EP EP25193499.8A patent/EP4653465A3/en active Pending
- 2019-09-20 EP EP19863329.9A patent/EP3852617B1/en active Active
-
2024
- 2024-04-09 JP JP2024062468A patent/JP2024096134A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022501368A5 (https=) | ||
| FI3852617T3 (fi) | Vasta-ainefragmenttien käyttö tikagrelorin aktiivisuuden kääntämiseen | |
| TW201834687A (zh) | 抗-cd19類美登醇(maytansinoid )免疫結合物抗體於治療b-細胞惡性症狀之用途 | |
| JP2019505527A5 (https=) | ||
| JP2020504110A5 (https=) | ||
| BR112013004850B1 (pt) | uso de um antagonista do tgf-b na preparação de um medicamento para tratamento de infarto do miocárdio | |
| KR20220019656A (ko) | 경쇄 아밀로이드증 치료 방법 | |
| JP2026048712A (ja) | 第ＸＩ／ＸＩａ因子抗体の医薬製剤および投薬レジメン | |
| CN116096874A (zh) | 用于治疗缺血的腺苷三磷酸双磷酸酶与p2y12抑制剂的组合 | |
| TWI804692B (zh) | 杜拉魯肽(dulaglutide)之治療用途 | |
| JP2023507795A5 (https=) | ||
| JP2025517443A (ja) | 抗インスリン受容体抗体のための製剤及びそれらの使用 | |
| TW202334239A (zh) | 因子XI/XIa抗體之投藥方案 | |
| JP2023550458A (ja) | 眼性疾患を治療する方法における使用のためのｖｅｇｆアンタゴニスト | |
| RU2021109688A (ru) | Способы устранения активности тикагрелора | |
| US12617870B2 (en) | Methods of reversing ticagrelor activity | |
| TWI886758B (zh) | 抗pvrig/抗tigit雙特異性抗體在治療惡性腫瘤中的用途 | |
| JP7574079B2 (ja) | 小児患者における癌の治療のためのラムシルマブ | |
| JP2019505516A (ja) | インターロイキン−１７（ｉｌ−１７）アンタゴニストを使用してざ瘡を治療する方法 | |
| WO2025130748A1 (zh) | 一种抗凝血因子XI/XIa抗体制剂 | |
| CN121889423A (zh) | 使用抗gfral抗体治疗恶心和呕吐病症的方法 |